AXDX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AXDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2025-03-26), the stock price of Accelerate Diagnostics is $0.969. Accelerate Diagnostics's graham number for the quarter that ended in Dec. 2024 was $N/A. Therefore, Accelerate Diagnostics's Price to Graham Number ratio for today is N/A.
The historical rank and industry rank for Accelerate Diagnostics's Graham Number or its related term are showing as below:
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
The historical data trend for Accelerate Diagnostics's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accelerate Diagnostics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Graham Number | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Accelerate Diagnostics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Graham Number | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Medical Devices subindustry, Accelerate Diagnostics's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Accelerate Diagnostics's Price-to-Graham-Number falls into.
Graham Number is a concept based on Ben Graham's conservative valuation of companies.
Accelerate Diagnostics's Graham Number for the fiscal year that ended in Dec. 2024 is calculated as
Graham Number | |||||
= | sqrt of (22.5 | * | Tangible Book per Share | * | EPS without NRI) |
= | sqrt of (22.5 | * | -2.238 | * | -2.158) |
= | N/A |
Accelerate Diagnostics's Graham Number for the quarter that ended in Dec. 2024 is calculated as
Graham Number | |||||
= | sqrt of (22.5 | * | Tangible Book per Share | * | EPS without NRI (TTM)) |
= | sqrt of (22.5 | * | -2.238 | * | -2.103) |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accelerate Diagnostics (NAS:AXDX) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Accelerate Diagnostics's Price to Graham number Ratio for today is calculated as
Price to Graham number | = | Share Price (Today) | / | Graham number (Q: Dec. 2024 ) |
= | 0.969 | / | N/A | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Thank you for viewing the detailed overview of Accelerate Diagnostics's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.
David Patience | officer: Chief Financial Officer | C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 240, TUCSON AZ 85714 |
John Patience | director, 10 percent owner | 28161 N. KEITH DRIVE, LAKE FOREST IL 60045 |
Jack W Schuler | director, 10 percent owner | 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045 |
Larry Michael Mertz | officer: Chief Technology Officer | 3950 S. COUNTRY CLUB ROAD, TUCSON AZ 85714 |
Jack Phillips | director, officer: PRESIDENT AND CEO | 11731 YALE DR, CARMEL IN 46032 |
Marran H. Ogilvie | director | 599 LEXINGTON AVENUE, NEW YORK NY 10022 |
Jennifer Regan | director | C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714 |
Mark S. Black | director | 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714 |
Steven Reichling | officer: CFO | 7000 NORTH BROADWAY, BUILDING 3-307, DENVER CO 80221 |
Ron Price | officer: SVP & HEAD OF COM OPS AMERICAS | 3950 SOUTH COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714 |
Wayne Burris | director | 3451 PLANO PARKWAY, LEWISVILLE TX 75056 |
Hany Massarany | director | 1910 INNOVATION PARK DR, TUCSON AZ 85737 |
Mark C Miller | director | C/O STERICYCLE INC., 28161 N KEITH DRIVE, LAKE FOREST IL 60045 |
Louise Francesconi | director | 870 WINTER STREET, WALTHAM MA 02451 |
Charles M Watts | director | 3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By GuruFocus News • 02-15-2025
By GuruFocus News • 01-08-2025
By GuruFocus Research • 02-06-2024
By GuruFocus News • 11-15-2024
By PRNewswire • 10-25-2024
By GuruFocus News • 02-06-2025
By GuruFocus Research • 02-06-2024
By PRNewswire • 05-02-2024
By GuruFocus Research • 05-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.